Home  /  Resource Library  /  Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

ASH 2019: Results of a study investigating Ibrutinib combined with Rituximab compared to standard chemoimmuinotherapy for first line treatment of CLL.